Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS

Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet need...
September 04, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis gibt Rücktritt von CEO Joseph Jimenez per 2018 bekannt. Ernennung von Vasant Narasimhan zum neuen CEO auf 1. Februar 2018.

Basel, 4. September 2017 - Joseph Jimenez, Chief Executive Officer (CEO) von Novartis, hat den Verwaltungsrat von seinem Wunsch in Kenntnis gesetzt, im Jahr 2018 nach achtjähriger Tätigkeit als CEO...
September 04, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis annonce que son Directeur général, Joseph Jimenez, a décidé de quitter la société en 2018. Vasant Narasimhan est nommé Directeur général, à compter du 1er février 2018.

Bâle, le 4 septembre 2017 - Joseph Jimenez, Directeur général (CEO) de Novartis, a informé le Conseil d'administration de son souhait de quitter ses fonctions de Directeur général en 2018, après avoir...
September 04, 2017 01:00 ET | Source: Novartis Pharma AG

Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.

Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position. The...
August 30, 2017 11:04 ET | Source: Novartis Pharma AG

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2]. Novel approach to cancer...
August 27, 2017 05:00 ET | Source: Novartis Pharma AG

Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885,...
August 27, 2017 05:00 ET | Source: Novartis Pharma AG

Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned

Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS...
August 24, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis appoints Bertrand Bodson as Chief Digital Officer

New leader to drive the digital transformation Novartis has embarked upon Basel, August 24, 2017 - Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for...
August 24, 2017 01:10 ET | Source: Novartis Pharma AG

Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Approval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk of disease progression or death by 43% versus letrozole alone[1] Kisqali plus letrozole...
August 21, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria

Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first compound...